| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2005 | US20050004056 Ptp10d, tec protein tyrosine kinase and edtp homologous proteins involved in the regulation of energy homeostasis |
| 01/06/2005 | US20050004055 Synergistic process; electrical stimulation; administering hyaluronidase |
| 01/06/2005 | US20050004051 Methods for treatment of bacterial infections in impaired renal patients |
| 01/06/2005 | US20050004050 for treating Gram-positive bacterial infection of skin and soft tissue; remains at therapeutic levels in the bloodstream for 7 days or longer |
| 01/06/2005 | US20050004049 Novel griseofulvin compositions |
| 01/06/2005 | US20050004047 Bactericides; antiprotozoa agents |
| 01/06/2005 | US20050004046 Administering flavonoids and oxidation resistance compound; Alzheimer's disease; Parkinson's disease; Huntington's disease |
| 01/06/2005 | US20050004045 Substances for use in treating psoriasis |
| 01/06/2005 | US20050004044 Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en-22-one 16-0-(2-0-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1->3)-(2-0-acetyl-alpha-L-arabinopyranoside)] or OSW-1 and its derivatives for cancer therapeutics |
| 01/06/2005 | US20050004043 Protease inhibitors; human t-cell leukemia virus; aids |
| 01/06/2005 | US20050004039 Selective analgesic agents |
| 01/06/2005 | US20050004030 Degradation spores; infection therapy |
| 01/06/2005 | US20050004027 Administering a compound which blocks endothelial growth factor |
| 01/06/2005 | US20050004026 Induction of capacse cascade ; administering apoptosis inducing protein; drug screening; anticancer agents |
| 01/06/2005 | US20050004023 Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment |
| 01/06/2005 | US20050004018 Use of antitumoral compound in cancer therapy |
| 01/06/2005 | US20050004017 Antiproliferative agents; anticarcinogenic agents |
| 01/06/2005 | US20050004015 Novel haemopoietin receptor and genetic sequences encoding same |
| 01/06/2005 | US20050004011 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes |
| 01/06/2005 | US20050004010 Complex with antitumor agents; therapy, diagnosis |
| 01/06/2005 | US20050004007 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| 01/06/2005 | US20050004005 Methods of treating diseases responsive to Induction of Apoptosis |
| 01/06/2005 | US20050004002 Mixture of drug with carrier such as protein; side effect reduction |
| 01/06/2005 | US20050003998 Therapeutic use of selective LXR modulators |
| 01/06/2005 | US20050003976 Mixture of vegetable oils, aromatic solvent and caffeine; nerve stimulant perfume; topical applying |
| 01/06/2005 | US20050003490 Immunoglobulins specific for cell surface protein for use in diagnosis, prevention and treatment of cell proliferative disorders; inhibitory action associated with reduced cellular transport of amino acids |
| 01/06/2005 | US20050003467 Such as epiephrine which is contacted with blood vessel that feeds nutrients to tumor tissue, and hemolyzing red blood cells; drug screening |
| 01/06/2005 | US20050003465 Monoclonal abtibody specific to prostate cell-surface antigen associated with androgen-dependent and androgen-independent prostate tumors for use in prevention, diagnosis and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy |
| 01/06/2005 | US20050003455 Using myocardial cells and/or cultured vascular endothelial cells as tools in identifying modulators of chloride channel transport and treatments for cardiovascular disorders; antiapoptosis |
| 01/06/2005 | US20050003451 Immunoglobulin for use in diagnosis, prevention and treatment of infection, autoimmune, inflammatory and cell proliferative diseases; immunotherapy |
| 01/06/2005 | US20050003448 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 01/06/2005 | US20050003442 Delta4-desaturase genes and uses thereof |
| 01/06/2005 | US20050003433 Recombinant neospora antigens and their uses |
| 01/06/2005 | US20050003409 Expression vector comprising nucleotide sequences coding polyketide synthase for use in transformation, and propagation of streptomyces cells capable of producing moxidectin; bactericides; nematocide |
| 01/06/2005 | US20050003400 Using osteoprotegrin binding agent as tool in identifying modulator for treatment and prevention of osteoporosis and bone disorders |
| 01/06/2005 | US20050003368 Cancer monitoring and therapeutics |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050003047 Intestinal mineral absorption capacity improver |
| 01/06/2005 | US20050003031 Anti-cancer compounds |
| 01/06/2005 | US20050003029 Treating retinal and choroidal edemas and/or hemorrhages; preserving eyesight |
| 01/06/2005 | US20050003024 Regulation of mammalian hair growth |
| 01/06/2005 | US20050003023 Topical composition for the treatment of psoriasis and related skin disorders |
| 01/06/2005 | US20050003021 Bowel cleansing agent |
| 01/06/2005 | US20050003020 Anti-viral compositions and methods of making and using the anti-viral compositions |
| 01/06/2005 | US20050003018 Removing amyloid deposits from brain without detrimental side effects; combining with such as clioquinol and vitamin B12; kits |
| 01/06/2005 | US20050003015 Producing isoleucine, leucine and valine containing particles having reduced bitterness and odor; small volume dose |
| 01/06/2005 | US20050003014 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 01/06/2005 | US20050003013 Controlled rate and duration of release; degradable gel with controlled saturated moisture content |
| 01/06/2005 | US20050003009 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| 01/06/2005 | US20050003007 Method of sterilization of polymeric microparticles |
| 01/06/2005 | US20050003005 Basic inorganic salt acid resistant coating; antiulcer agents, benzimidazole derivatives |
| 01/06/2005 | US20050003004 Pharmaceutical formulation comprising a water-insoluble active agent |
| 01/06/2005 | US20050003003 Modulation of release from dry powder formulations |
| 01/06/2005 | US20050003002 Tramadol hydrochloride with such as diclofenac sodium; reduced water solubility |
| 01/06/2005 | US20050003001 Including floating agent |
| 01/06/2005 | US20050003000 Method for the the formation of ibuprofen crystals |
| 01/06/2005 | US20050002997 Enhancing release of adverse agent upon exposure to solvents; drug abuse prevention |
| 01/06/2005 | US20050002992 Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| 01/06/2005 | US20050002991 Prophylactic agent of hypertension containing a conjugated fatty acid as an effective ingredient and the use thereof |
| 01/06/2005 | US20050002988 Nutritional composition for controlling blood sugar level |
| 01/06/2005 | US20050002986 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/06/2005 | US20050002983 Drug eluting stents having different symptom reducing agents |
| 01/06/2005 | US20050002979 Topical urea application; protecting and repairing skin |
| 01/06/2005 | US20050002969 Binary composition for prime-boost release of active ingredients like vaccines |
| 01/06/2005 | US20050002964 Adhesion inhibition of fungi |
| 01/06/2005 | US20050002961 Concentrate comprising green tea, grape skin extract and grape extract, the production thereof and use of the same |
| 01/06/2005 | US20050002947 Screening candidate anthelmintic materials for immobilization and toxicity activity |
| 01/06/2005 | US20050002938 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/06/2005 | US20050002928 Treatment with anti-ErbB2 antibodies |
| 01/06/2005 | US20050002901 Compositions and methods for treating coronavirus infection and SARS |
| 01/06/2005 | US20050002900 Inhibiting estradiol production in human adipocytes using interferon gamma and/or tumor necrosis factor antagonist and/or interleukin-1 antagonist; reducing side effects |
| 01/06/2005 | US20050002895 Methods and compositions for controlled release of drugs |
| 01/06/2005 | US20050002880 Cosmetic or dermatological preparations containing one or more ketohexoses |
| 01/06/2005 | US20050002879 Containing N-acetylglucosamine, retinoids and pro-vitamin A; promoting production of epidermal hyaluronic acid; improving firmness and moisture retention |
| 01/06/2005 | US20050002878 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 01/06/2005 | US20050002877 Aqueous solution containing sodium monofluorophosphate, sodium fluoride, sorbitol and cellulose gum; appendage housing device; safe, external application |
| 01/06/2005 | US20050002876 Oral care methods and products |
| 01/06/2005 | US20050002870 Spray drying; needleless injection |
| 01/06/2005 | US20050002868 Method of treatment of a female suffering from androgen insufficiency |
| 01/06/2005 | US20050002867 Buccal, polar and non-polar sprays containing propofol |
| 01/06/2005 | US20050002861 Technetium isotope; accumulating in situ site of pathology; radiolabeled peptide |
| 01/06/2005 | US20050000387 Wood preservative with alkaline copper quaternary |
| 01/06/2005 | CA2567746A1 Methods for treating cognitive impairment and improving cognition |
| 01/06/2005 | CA2556706A1 Treatment of amyloid- and epileptogenesis-associated diseases |
| 01/06/2005 | CA2535980A1 P38 kinase inhibitor compositions and methods of use |
| 01/06/2005 | CA2531582A1 Composition and method for treating upper abdominal pain and cramping |
| 01/06/2005 | CA2531107A1 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 01/06/2005 | CA2531101A1 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 01/06/2005 | CA2531058A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/06/2005 | CA2531020A1 Cannabinoid receptor modulator |
| 01/06/2005 | CA2531017A1 Composition for external use |
| 01/06/2005 | CA2530668A1 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 01/06/2005 | CA2530662A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 01/06/2005 | CA2530649A1 Antiepileptic agent |
| 01/06/2005 | CA2530582A1 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 01/06/2005 | CA2530581A1 Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 01/06/2005 | CA2530385A1 Melt extruded controlled release oxycodone multiparticulates |
| 01/06/2005 | CA2530381A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic or antidepressant agent, and use thereof for the preparationof a medicament that prevents the adverse effects of psychotropic drugs |
| 01/06/2005 | CA2530376A1 Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |